Has Peter Karachunski, MD received payments from drug or device companies?

Yes. Drug and device makers reported $21,649 in general payments to Peter Karachunski, MD across 35 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Peter Karachunski, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Peter Karachunski, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Peter Karachunski, MD

Child & Adolescent Psychiatry · Minneapolis, MNNPI 1720176308

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,515 of the $21,649 with a category attached, or 67.0%. 5 manufacturers reported payments, led by Sarepta Therapeutics, Inc. at 57.8% of the total. Among child & adolescent psychiatry clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,649in general payments, 2019–2025

Across 35 payments — averaging $618.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sarepta Therapeutics, Inc.$13K
Pfizer$4K
PTC Therapeutics, Inc.$3K
Biogen$2K
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$135

$620,324in research payments, 2019–2025

Across 130 payments — averaging $4771.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

PTC Therapeutics, Inc.$370K
Sarepta Therapeutics, Inc.$75K
Pfizer$55K
Novartis$40K
Harmony Biosciences LLC$35K
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$25K
plus $19K from 1 others

What the payments were for

Consulting fees$14,51567%
Speaking & faculty fees$3,33515%
Travel & lodging$2,74913%
Food & beverage$1,0505%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sarepta Therapeutics, Inc.	14	$12,504
Pfizer	4	$4,124
PTC Therapeutics, Inc.	11	$3,189
Biogen	4	$1,697
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)	2	$135

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Elevidys$12,204
EMFLAZA$2,951
SPINRAZA$1,575

How this compares

$21,649 in reported general payments places this provider in the 95th percentile of 21 child & adolescent psychiatry providers in Minnesota.

See all child & adolescent psychiatry providers in Minnesota →

Medicare billing

Part B allowed, 2024

$13,361

Medicare patients

Services billed

201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EvrysdiRisdiplam	90	$2,566,169
KeveyisDichlorphenamide	11	$243,912
NayzilamMidazolam	23	$34,720
BriviactBrivaracetam	13	$17,979
Pyridostigmine Bromide	42	$5,908
Mexiletine Hcl	24	$3,660
Azathioprine	28	$2,538
Lisdexamfetamine Dimesylate	11	$2,225
Acetazolamide	17	$2,045
Mycophenolate Mofetil	15	$1,972
Divalproex Sodium	13	$682
Modafinil	11	$563
Lacosamide	18	$438
Gabapentin	30	$331
Prednisone	36	$330

Paid to pharmacies, not to this prescriber.

Other child & adolescent psychiatry in Minneapolis

Jonathan JensenMinneapolis$109
Suzy PetersonMinneapolis$49
Phillip EdwardsonMinneapolis$13
Adam FoxMinneapolis$10
Kim HoltmeierGolden Valley$5K
Israel SokeyePlymouth$1K
Sreelatha SpiekerMankato$854
Carl HansenSt Louis Park$396
Travis HansenMankato$358
Michael AdelmanBaxter$313

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →